aTyr Pharma, Inc

aTyr Pharma is a U.S.-based biotechnology company focused on discovering and developing protein-based therapeutics derived from tRNA synthetase biology. Its pipeline includes efzofitimod for inflammatory lung disease and ATYR0101 and ATYR0750, which are being studied for fibrosis and related inflammatory conditions. The company is organized around research, clinical development, and partnering from its San Diego base, with a majority-owned subsidiary in Hong Kong.

−40 506,8 %

−39 009,5 %

−19,1 %

5.30

5.30

— aTyr Pharma, Inc
%
Efzofitimod45% Clinical-stage biologic candidate developed for inflammatory lung disease, including ILD and pulmonary sarcoidosis.
ATYR010125% Preclinical and translational anti-fibrotic program studied in lung, kidney, and other fibrotic diseases.
ATYR075015% Protein-based therapeutic program centered on FGFR4 biology and inflammation/fibrosis pathways.
Collaboration and licensing revenue15% Partner-funded development rights, milestones, and potential royalties from regional licensing deals.

aTyr does not sell commercial medicines broadly; its economic counterparties are primarily pharmaceutical partners,...

  • Strategic licensing partnersprimary

    Partners such as Kyorin that obtain regional rights and fund development, regulatory, and commercialization work.

  • Clinical trial ecosystemprimary

    Investigators, CROs, and trial sites that conduct studies needed to advance product candidates.

  • Future specialty prescriberssecondary

    Pulmonologists and other specialists who would prescribe approved therapies for ILD or fibrosis.

  • Patients with inflammatory and fibrotic diseasesecondary

    End patients who would receive efzofitimod or related therapies if approved.

aTyr is headquartered and conducts substantially all of its activities in San Diego, California, while also...

  • •San Diego, California is the main operating and R&D base
  • •Delaware is the parent-company legal domicile
  • •Hong Kong subsidiary is consolidated in the financial statements
  • •Japan is the key partnered commercialization market for efzofitimod
  • •Commercial infrastructure would need to be built market by market

aTyr’s strategy centers on advancing differentiated protein-based drug candidates through clinical development and...

01
Advance clinical programsshort-term

Clinical proof-of-concept is the main driver of value in a pre-commercial biotech model.

02
Expand partnering and licensingmedium-term

Regional partners can fund development and create non-dilutive capital sources.

03
Build commercialization readiness selectivelymedium-term

If approval approaches, the company needs market access, distribution, and stakeholder capabilities.

The company faces the core biotech risks of clinical failure, regulatory uncertainty, and the possibility that its...

critical

Clinical development failure

The company’s value depends on proving that efzofitimod and other candidates are safe and effective.

Scope
Efzofitimod, ATYR0101, ATYR0750
Materiality
high
high

Regulatory pathway uncertainty

Pulmonary sarcoidosis lacks an established FDA approval pathway, increasing approval risk even after positive data.

Scope
EFZO-FIT study
Materiality
high
high

Financing and dilution risk

The company has not generated substantial product revenue and relies on equity, partnerships, and licensing.

Scope
ATM program and future capital raises
Materiality
high
high

Commercialization execution risk

It has no sales, marketing, or distribution infrastructure and may need third parties to commercialize products.

Scope
Future approved products
Materiality
high
high

IP and patent risk

Loss or narrowing of patent protection could reduce exclusivity and bargaining power.

Scope
Product candidates and platform biology
Materiality
high
medium

Competitive pressure

Large pharmaceutical and biotech companies are developing therapies in ILD and fibrosis.

Scope
Inflammatory lung disease and fibrosis markets
Materiality
medium
Research and development expense accruals
Affects operating expense timing and quarterly comparability
Collaboration and milestone revenue recognition
Affects reported revenue timing and volatility
Stock-based compensation
Affects R&D and G&A expense
Fair value of investments and cash equivalents
Affects liquidity presentation and other comprehensive income

aTYR PHARMA INC

ATYR · Biological Products, (No Diagnostic Substances)

GYRE THERAPEUTICS, INC.

GYRE · Pharmaceutical Preparations

ALNYLAM PHARMACEUTICALS, INC.

ALNY · Pharmaceutical Preparations

Lyra Therapeutics, Inc.

LYRA · Surgical & Medical Instruments & Apparatus

Iterum Therapeutics plc

ITRMF · Pharmaceutical Preparations

Aldeyra Therapeutics, Inc.

ALDX · Pharmaceutical Preparations

: 29.4.2026